Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
58.237,73
0,00%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kura Oncology Inc (KURA) Kura Oncology Inc (KURA) Notizie

Kura Oncology Inc

KURA
20,28
0,66 (3,36%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 23:30:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202413:30GLOBEKura Oncology to Report First Quarter 2024 Financial Results
22/4/202413:30GLOBEKura Oncology Receives Breakthrough Therapy Designation for..
10/4/202413:30GLOBEKura Oncology to Participate in Stifel Targeted Oncology..
05/4/202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
06/3/202413:30GLOBEKura Oncology Reports First Patient Dosed in Trial of..
01/3/202423:00GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
27/2/202422:52EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202422:03EDGAR2Form 8-K - Current report
27/2/202422:01GLOBEKura Oncology Reports Fourth Quarter and Full Year 2023..
26/2/202413:30GLOBEKura Oncology Doses First Patient in KOMET-008 Trial of..
22/2/202413:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
20/2/202413:30GLOBEKura Oncology to Report Fourth Quarter and Full Year 2023..
15/2/202422:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
14/2/202423:58EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202423:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202423:21EDGAR2Form S-3 - Registration statement under Securities Act of..
02/2/202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
31/1/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202422:10EDGAR2Form 144 - Report of proposed sale of securities
30/1/202413:08EDGAR2Form 8-K - Current report
30/1/202413:00GLOBEKura Oncology Reports Positive Preliminary Ziftomenib..
26/1/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202422:08EDGAR2Form 8-K - Current report
24/1/202422:12EDGAR2Form 144 - Report of proposed sale of securities
24/1/202413:00GLOBEKura Oncology Announces Oversubscribed $150 Million Private..
04/1/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202315:01EDGAR2Form 8-K - Current report
11/12/202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202313:30GLOBEKura Oncology’s Menin Inhibitor Ziftomenib Selected for The..
28/11/202313:30GLOBEKura Oncology to Participate in the JMP Securities..
02/11/202321:39EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:03EDGAR2Form 8-K - Current report
02/11/202321:01GLOBEKura Oncology Reports Third Quarter 2023 Financial Results
02/11/202312:30GLOBEKura Oncology and Mirati Therapeutics Enter into Clinical..
30/10/202312:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
26/10/202322:05GLOBEKura Oncology to Report Third Quarter 2023 Financial Results
19/10/202313:30GLOBEKura Oncology Announces First Patient Dosed in FIT-001 Trial..
17/10/202322:05GLOBEKura Oncology Announces Positive Results from..
04/10/202313:30GLOBEKura Oncology Announces Three Presentations at..
28/9/202313:30GLOBEKura Oncology Reports Preclinical Data Showing Ability of..
19/9/202313:30GLOBEKura Oncology to Participate in Cantor Global Healthcare..
Apertura: 19,63 Min: 19,63 Max: 20,81
Chiusura: 19,62

La tua Cronologia

NASDAQ
KURA
Kura Oncology
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network